Evaluation of Metabolic Activity of Liver Metastases by FDG-PET Scanning

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Radboud University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Radboud University
ClinicalTrials.gov Identifier:
NCT00184782
First received: September 12, 2005
Last updated: September 20, 2007
Last verified: September 2005
  Purpose

The purpose of this study is to evaluate the effect of primary tumor resection on the metabolic activity of metastases in patients with a colorectal primary tumor and synchronous liver metastases by positron emission tomography (PET) with 2-deoxy-2-fluoro[18F]-D-glucose (FDG-PET) scanning.


Condition Intervention
Colorectal Neoplasms
Procedure: FDG-PET

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Exploratory Study on FDG-PET Scanning in Evaluating the Metabolic Activity of Liver Metastases Before and After Resection of the Primary Tumor in Patients With a Colorectal Malignancy

Resource links provided by NLM:


Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Increase in metabolic activity of liver metastases after resection of the primary tumor compared to the activity of metastases in patients without primary tumor resection

Estimated Enrollment: 30
Study Start Date: September 2003
Estimated Study Completion Date: December 2008
Detailed Description:

The goal of this study is to evaluate the activity of liver metastases before and after resection of the primary tumor. Non-invasive assessment of tumor metabolism is possible in vivo by means of positron emission tomography (PET)-scanning. Therefore, FDG-PET scan offers a suitable approach to determine the influence of removal of a primary colorectal tumor on metabolic activity of the liver metastases. The FDG uptake in the liver metastases is quantified by calculating standardised uptake values (SUVs).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Colorectal cancer and synchronous liver metastases

Exclusion Criteria:

  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00184782

Contacts
Contact: Charlotte Peeters, MD +31-24-3611111 ext 17365 C.Peeters@chir.umcn.nl
Contact: Theo Ruers, PhD +31-24-3611111 ext 17365 T.Ruers@chir.umcn.nl

Locations
Netherlands
Radboud University Nijmegen Medical Centre Recruiting
Nijmegen, Gelderland, Netherlands, 6500 HB
Contact: Charlotte Peeters, MD    +31-24-3611111 ext 17365    C.Peeters@chir.umcn.nl   
Contact: Theo Ruers, PhD    +31-24-3611111 ext 17365    T.Ruers@chir.umcn.nl   
Sponsors and Collaborators
Radboud University
Investigators
Principal Investigator: Theo Ruers, PhD Radboud University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00184782     History of Changes
Other Study ID Numbers: CP 2005
Study First Received: September 12, 2005
Last Updated: September 20, 2007
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:
colorectal cancer
liver metastases
metabolic activity

Additional relevant MeSH terms:
Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Liver Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases

ClinicalTrials.gov processed this record on April 17, 2014